Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

OHSU studying drug for bone-deforming disorder

22.05.2006


Researchers seek therapy for osteogenesis imperfecta, which can lead to hundreds of fractures in a lifetime



Jimmy Fox isn’t typical of a person with the genetic, "brittle bone" disorder osteogenesis imperfecta (OI). He lifts weights almost daily, participates in grueling wheelchair races, chops wood and enjoys hunting in rough backcountry.

Still, Fox, who owns a busy combination grocery store-gun shop in Cloverdale, Ore., is eager to participate in an Oregon Health & Science University-led study of a drug that may help reduce the debilitating effects of OI, an inherited disorder characterized by weak bones that break easily. People with the most severe forms of OI have short stature, can suffer hundreds if not thousands of fractures in a lifetime, and are confined to a wheelchair.


"I didn’t think it could do me any harm," Fox, 40, said of the study. He has a less-severe form of OI, allowing him to be more mobile - he walks on his hands when he’s not in his wheelchair - and suffer fewer fractures than many others with the disorder. Fox had both of his legs amputated when he was 18 due to continued fracturing. "The study might do me some good, so I thought I might as well do it and give it a try. It will help other people."

The alternative is unacceptable to Fox, who acknowledges that his significant upper-body strength has kept many of the disorder’s most debilitating effects at bay. "They told me ’If you weren’t as active as you are, you would be totally screwed up by now.’ To be honest, that’s what really swayed me to do this."

The study, headed by Eric Orwoll, M.D., professor of medicine (endocrinology, diabetes and clinical nutrition) and director of the Bone and Mineral Unit, OHSU School of Medicine, is examining the effectiveness of the synthesized parathyroid hormone, teriparatide, in increasing bone mass and improving bone structure in adults affected by OI. Teriparatide, derived from the human parathyroid gland, is manufactured and sold by Eli Lilly and Co. under the brand name FORTEO.

FORTEO already is approved for use by men and postmenopausal women with osteoporosis who are at high risk for having fractures, according to Lilly’s Web site.

"It gives a lot of hope to a lot of people who wouldn’t have much to look forward to," Orwoll said.

In most OI patients, the disorder is caused by a mutation in one of two genes, COL1A1 and COL1A2, that encode for type 1 collagen, the fibrous protein that serves as the scaffolding for bone and which also is present in ligaments, tendons, teeth, the white portion of the eyes, and even skin. The defect impairs the body’s ability to mineralize bone and other collagen-containing tissue, leading to bone fragility, loose joints, eye discoloration, dental problems and premature hearing loss.

Although exact incidence isn’t known, OI is believed to affect 1 of every 5,000 to 10,000 individuals of all racial and ethnic origins, with between 20,000 and 50,000 Americans living with the disorder. Parents with OI have a 50 percent chance with each pregnancy of having an affected child and most children with the disorder have inherited it from a parent. About a fourth of all children with OI are born into families with no history of the disorder.

Janet Reeder, M.S., PA-C, a former faculty member of the OHSU Bone and Mineral Unit who developed the study, said people with OI are largely ignored by the medical community because few treatment options exist, or doctors fear treatment will cause more fractures.

"Many practitioners say, ’We don’t know what to do with you. Sorry, have a nice life,’" Reeder said. "But they pay taxes, they work full time. They have incredible tenacity. This is a group of people that has really triumphed over a lot of disability and deformity. What we’re trying to do is help them by hopefully decreasing fractures and thereby increasing quality of life."

There is no cure for the disorder, and while drugs have been studied for use in children with OI, there is no established medical therapy for affected adults. Adult OI treatment varies depending on the degree of impairment and the patient’s age. Doctors sometimes surgically implant rods to support long bones or prescribe braces to support lower limbs. Patients also are encouraged to take calcium and vitamin D supplements daily.

"What we’re interested in is, after kids make it through childhood and into adulthood, what can we do for them?" Orwoll said.

Each of the three national study sites - OHSU, Kennedy Krieger Institute at Johns Hopkins University, and Baylor School of Medicine - are recruiting a total of 90 men and women ages 18 and older for the 18-month, blinded trial. Participants will receive either FORTEO or a placebo, which is self-administered once a day using an injection pen. They will be examined at the first, third, sixth, 12th and 18th months after initial screening, and their spine, hip, forearm and total body bone mineral density will be measured every six months.

FORTEO offers hope of suffering fewer bone fractures for individuals with OI such as Anton Borissov, a 40-year-old Portland resident who has never walked and lives in his wheelchair. It also will increase awareness about the disorder, which may lead to even more drug therapies.

"For me, it is a big, big thing not to have breaks. When I lift something it’s just ’break, break, break,’" said Borissov, a native of Russia who estimates he’s suffered a thousand fractures in his lifetime, and who can break ribs just by coughing. He is not a participant in the FORTEO study. "If they’re doing this study, it’s good. And people will know something about OI, even doctors, and that I’m no different."

Jonathan Modie | EurekAlert!
Further information:
http://www.ohsu.edu

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>